Skip to main content
Erschienen in: Osteoporosis International 12/2011

01.12.2011 | Original Article

Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis

verfasst von: G. Wheater, V. E. Hogan, Y. K. O. Teng, J. Tekstra, F. P. Lafeber, T. W. J. Huizinga, J. W. J. Bijlsma, R. M. Francis, S. P. Tuck, H. K. Datta, J. M. van Laar

Erschienen in: Osteoporosis International | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Summary

The role of B cells in inflammatory bone formation and resorption is controversial. We investigated this in patients with rheumatoid arthritis (RA) treated with rituximab, a B-cell depleting antibody. We found a significant suppression in bone turnover, possibly a direct effect or as a consequence of a reduction in inflammation and disease activity.

Introduction

RA is the most prevalent inflammatory joint disease, in which B cells play an important role. However, the role of B cells in bone turnover is controversial and RA subjects treated with rituximab, a B-cell depleting monoclonal antibody, provide an ideal model for determining the role of B cells in inflammatory bone resorption.

Methods

Serum from 46 RA patients, collected pre- and post-rituximab therapy, was analysed for biomarkers of bone turnover (procollagen type I amino-terminal propeptide [P1NP], osteocalcin, β-isomerised carboxy-terminal telopeptide of type 1 collagen [βCTX] and osteoprotegerin [OPG]).

Results

A significant decrease in bone resorption was observed 6 months after rituximab (median change βCTX −50 ng/L, 95%CI −136, −8 p < 0.001, this equates to −37%; 95%CI −6, −49), mirrored by a reduction in disease activity. Similarly, there was a significant increase in P1NP, a marker of bone formation (median change P1NP 5.0 μg/L, 95%CI −1.0, 11.2, p = 0.02; 13%; 95%CI −3, 39), but no significant change in osteocalcin or OPG levels. The percentage change from baseline of βCTX in a subgroup of patients (not on prednisolone or bisphosphonate) was significantly correlated with the percentage reduction in DAS28 score (r s = 0.570, p = 0.014).

Conclusions

In conclusion, we have found that B-cell depletion increases bone formation and decreases bone resorption in RA patients; this may be a direct effect on osteoblasts and osteoclasts, respectively, and be at least partially explained by the decreased inflammation and disease activity.
Literatur
1.
Zurück zum Zitat Datta HK, Ng FW, Walker JA, Tuck SP, Varanasi SS (2008) The cell biology of bone metabolism. J Clin Pathol 61:577–587PubMedCrossRef Datta HK, Ng FW, Walker JA, Tuck SP, Varanasi SS (2008) The cell biology of bone metabolism. J Clin Pathol 61:577–587PubMedCrossRef
2.
Zurück zum Zitat Choi Y, Woo KM, Ko S-H, Lee YJ, Park S-J, Kim H-M, Kwon BS (2001) Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8+ T cells. Eur J Immunol 31:2179–2188PubMedCrossRef Choi Y, Woo KM, Ko S-H, Lee YJ, Park S-J, Kim H-M, Kwon BS (2001) Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8+ T cells. Eur J Immunol 31:2179–2188PubMedCrossRef
3.
Zurück zum Zitat Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Y-i N, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M (2001) Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167:2625–2631PubMed Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Y-i N, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M (2001) Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167:2625–2631PubMed
4.
Zurück zum Zitat Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N (2007) Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903–5909PubMedCrossRef Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N (2007) Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903–5909PubMedCrossRef
5.
Zurück zum Zitat Neale Weitzmann M, Cenci S, Haug J, Brown C, DiPersio J, Pacifici R (2000) B lymphocytes inhibit human osteoclastogenesis by secretion of TGFβ. J Cell Biochem 78:318–324CrossRef Neale Weitzmann M, Cenci S, Haug J, Brown C, DiPersio J, Pacifici R (2000) B lymphocytes inhibit human osteoclastogenesis by secretion of TGFβ. J Cell Biochem 78:318–324CrossRef
6.
Zurück zum Zitat Garcia-Perez MA, Noguera I, Hermenegildo C, Martinez-Romero A, Tarin JJ, Cano A (2006) Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. Hum Reprod 21:880–887PubMedCrossRef Garcia-Perez MA, Noguera I, Hermenegildo C, Martinez-Romero A, Tarin JJ, Cano A (2006) Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. Hum Reprod 21:880–887PubMedCrossRef
7.
Zurück zum Zitat Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y (2000) Prostaglandin E2 induces expression of receptor activator of nuclear factor-κB ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15:1321–1329PubMedCrossRef Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y (2000) Prostaglandin E2 induces expression of receptor activator of nuclear factor-κB ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15:1321–1329PubMedCrossRef
8.
Zurück zum Zitat Lee S-K, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA (2006) Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 21:695–702PubMedCrossRef Lee S-K, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA (2006) Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 21:695–702PubMedCrossRef
9.
Zurück zum Zitat Li Y, Li A, Yang X, Neale Weitzmann M (2007) Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100:1370–1375PubMedCrossRef Li Y, Li A, Yang X, Neale Weitzmann M (2007) Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100:1370–1375PubMedCrossRef
10.
Zurück zum Zitat Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian W-P, Neale Weitzmann M (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839–3848PubMedCrossRef Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian W-P, Neale Weitzmann M (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839–3848PubMedCrossRef
11.
Zurück zum Zitat Edwards JCW, Szczepanski L, Szechinski J, Flipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRef Edwards JCW, Szczepanski L, Szechinski J, Flipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRef
12.
Zurück zum Zitat Kelly CA, Bartholomew P, Lapworth A, Basu A, Hamilton J, Haycock C (2002) Peripheral bone density in patients with rheumatoid arthritis and factors which influence it. Eur J Intern Med 13:423–427PubMedCrossRef Kelly CA, Bartholomew P, Lapworth A, Basu A, Hamilton J, Haycock C (2002) Peripheral bone density in patients with rheumatoid arthritis and factors which influence it. Eur J Intern Med 13:423–427PubMedCrossRef
13.
Zurück zum Zitat Meier C, Seibel MJ, Kraenzlin ME (2009) Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24:386–388PubMedCrossRef Meier C, Seibel MJ, Kraenzlin ME (2009) Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24:386–388PubMedCrossRef
14.
Zurück zum Zitat Bonnick SL, Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119(4 Suppl 1):S25–S31PubMedCrossRef Bonnick SL, Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119(4 Suppl 1):S25–S31PubMedCrossRef
15.
Zurück zum Zitat Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JWJ, van Laar JM (2009) Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis 68:1075–1077PubMedCrossRef Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JWJ, van Laar JM (2009) Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis 68:1075–1077PubMedCrossRef
16.
Zurück zum Zitat Fransen J, van Riel PLCM (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(Suppl 39):S93–S99PubMed Fransen J, van Riel PLCM (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(Suppl 39):S93–S99PubMed
17.
Zurück zum Zitat Bongartz TA, Scholmerich J, Straub RH (2005) Osteoporosis in postmenopausal women. In: Maricic M, Gluck OS (eds) Bone disease in rheumatology. Lippincott Williams and Wilkens, Arizona, p 155 Bongartz TA, Scholmerich J, Straub RH (2005) Osteoporosis in postmenopausal women. In: Maricic M, Gluck OS (eds) Bone disease in rheumatology. Lippincott Williams and Wilkens, Arizona, p 155
18.
Zurück zum Zitat Hein G, Eidner T, Oelzner P, Rose M, Wilke A, Wolf G, Franke S (2010) Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int. doi:10.1007/s00296-010-1560-9 Hein G, Eidner T, Oelzner P, Rose M, Wilke A, Wolf G, Franke S (2010) Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int. doi:10.​1007/​s00296-010-1560-9
19.
Zurück zum Zitat Barnabe C, Hanley DA (2008) Effect of tumour necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 39:116–122PubMedCrossRef Barnabe C, Hanley DA (2008) Effect of tumour necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 39:116–122PubMedCrossRef
20.
Zurück zum Zitat Lange U, Teichmann J, Müller-Ladner SJ (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology 44:1546–1548PubMedCrossRef Lange U, Teichmann J, Müller-Ladner SJ (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology 44:1546–1548PubMedCrossRef
21.
Zurück zum Zitat Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BAC, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFкB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499PubMedCrossRef Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BAC, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFкB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499PubMedCrossRef
22.
Zurück zum Zitat Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353–357PubMedCrossRef Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353–357PubMedCrossRef
23.
Zurück zum Zitat Lems WF (2007) Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 56:3518–3522PubMedCrossRef Lems WF (2007) Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 56:3518–3522PubMedCrossRef
24.
Zurück zum Zitat Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Kalervo Väänänen H (2004) Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279:18361–18369PubMedCrossRef Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Kalervo Väänänen H (2004) Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279:18361–18369PubMedCrossRef
25.
Zurück zum Zitat Breuil V, Euller-Ziegler L (2006) Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73:349–354PubMedCrossRef Breuil V, Euller-Ziegler L (2006) Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73:349–354PubMedCrossRef
26.
Zurück zum Zitat Jimenez-Boj E, Redlich K, Türk B, Hanslik-Schnabel B, Wanivenhaus A, Chott A, Smolen JS, Schett G (2005) Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 175:2579–2588PubMed Jimenez-Boj E, Redlich K, Türk B, Hanslik-Schnabel B, Wanivenhaus A, Chott A, Smolen JS, Schett G (2005) Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 175:2579–2588PubMed
27.
Zurück zum Zitat Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30–S44PubMedCrossRef Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30–S44PubMedCrossRef
28.
Zurück zum Zitat Wichers M, Schmidt E, Bidlingmaier F, Klingmüller D (1999) Diurnal rhythm of cross laps in human serum. Clin Chem 45:1858–1860PubMed Wichers M, Schmidt E, Bidlingmaier F, Klingmüller D (1999) Diurnal rhythm of cross laps in human serum. Clin Chem 45:1858–1860PubMed
29.
Zurück zum Zitat Bjarnason NH, Henriksen EEG, Alexandersen P, Christgau S, Henriksen DB, Christiansen C (2002) Mechanism of circadian variation in bone resorption. Bone 30:307–313PubMedCrossRef Bjarnason NH, Henriksen EEG, Alexandersen P, Christgau S, Henriksen DB, Christiansen C (2002) Mechanism of circadian variation in bone resorption. Bone 30:307–313PubMedCrossRef
Metadaten
Titel
Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis
verfasst von
G. Wheater
V. E. Hogan
Y. K. O. Teng
J. Tekstra
F. P. Lafeber
T. W. J. Huizinga
J. W. J. Bijlsma
R. M. Francis
S. P. Tuck
H. K. Datta
J. M. van Laar
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 12/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1607-0

Weitere Artikel der Ausgabe 12/2011

Osteoporosis International 12/2011 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.